Latanoprost, an ocular hypotensive agent, is a rationally designed synthetic ester prodrug analogue of prostaglandin F2α (PGF2α) which was first reported in the early ‘90s.1 It is on the World Health Organization’s List of Essential Medicines and in the top 100 most commonly prescribed medication in the United States. It is used for treatment of ocular hypertension and open angle glaucoma.2
C2 PHARMA is the exclusive distributor of Latanoprost manufactured by Laurus Labs Limited, one of the world’s leading API manufacturers.
Latanoprost as a 0.005% ophthalmic solution is used for the reduction of elevated intraocular pressure in patients who have been diagnosed with open-angle glaucoma or ocular hypertension.
MECHANISM OF ACTION
Latanoprost lowers the intraocular pressure (IOP) by increasing uveoscleral outflow, with little or no effect on the conventional aqueous outflow facility.3 This enhanced uveoscleral outflow is the main reason for its hypotensive activity, while it also has minor effects on trabecular outflow and aqueous flow.4 One potential mechanism behind the effects on outflow is the regulation of matrix metalloproteinases and remodeling of the extracellular matrix, which changes the permeability of tissues associated with the outflow pathways resulting in alterations in outflow resistance and/or outflow rates.4
- Stjernschantz B. et al. J. Med. Chem. 1993, 36, 243-248.
- Toris, C.B., Camras, C.B., Yablonski, M.E., Ophthalmology. 1993, 100, 1297-1304.
- Toris C.B., Gabelt B.T., Kaufman P.L. Surv. Ophthalmol. 2008, 53, 107-120.